Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01849263 · ClinicalTrials.gov registry record · Phase 2

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

A Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
41
Enrollment target
13
Study locations

NCT01849263: Active Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, sponsored by National Cancer Institute (NCI).

NCT01849263 is a Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, above the 35-participant average among 11 other Recurrent Grade 1 Follicular Lymphoma trials with a reported enrollment target (17% higher). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01849263, a Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
41 participants
Enrollment target
13
Study locations

Study Summary

This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Primary Outcome

Overall response rate defined as a partial response (PR) or complete response (CR) as the objective status at any time during treatment, evaluated using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated. A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant ma

Conditions Studied

Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Refractory Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Ibrutinib

Study Locations (13)

Minnesota

  • Mayo Clinic in Rochester - Rochester
  • Metro Minnesota Community Oncology Research Consortium - Saint Louis Park
  • Park Nicollet Clinic - Saint Louis Park - Saint Louis Park

Ontario

  • Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
  • Kingston Health Sciences Centre - Kingston
  • University Health Network-Princess Margaret Hospital - Toronto

Other

  • National University Hospital Singapore - Singapore
  • National Cancer Centre Singapore - Singapore

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Wisconsin

  • University of Wisconsin Carbone Cancer Center - University Hospital - Madison

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2013-04-02
Est. Completion 2026-03-19
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT01849263 still lists

NCT01849263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, above the 35-participant average among 11 other Recurrent Grade 1 Follicular Lymphoma trials with a reported enrollment target (17% higher).

The record links to 5 conditions, with Recurrent Grade 1 Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01849263 lists 13 locations in 8 states (Minnesota, Ontario, Other).

Frequently Asked Questions

What is clinical trial NCT01849263 about?

NCT01849263 is a clinical study titled "Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma". This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

What is the current status of trial NCT01849263?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2013-04-02. Estimated completion is 2026-03-19.

What conditions does trial NCT01849263 study?

This clinical trial studies the following conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Refractory Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma.

What interventions are being tested in trial NCT01849263?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT01849263?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01849263 being conducted?

This trial has 13 study locations across Arizona, Florida, Minnesota, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Grade 1 Follicular Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01849263's enrollment target sits among peer trials

41 4th of 11 higher than 7 of 11 other Recurrent Grade 1 Follicular Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Grade 1 Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01849263, the US trial registry maintained by the National Library of Medicine. NCT01849263 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.